Snyder Karen Chin, Cunningham Justine, Huang Yimei, Zhao Bo, Dolan Jennifer, Wen Ning, Chetty Indrin J, Shah Mira M, Siddiqui Salim M
Department of Radiation Oncology, Henry Ford Health Systems, Detroit, Michigan.
Adv Radiat Oncol. 2021 Feb 6;6(4):100663. doi: 10.1016/j.adro.2021.100663. eCollection 2021 Jul-Aug.
Treatment planning of skull based meningiomas can be difficult due to the irregular shaped target volumes and proximity to critical optic structures. This study evaluated the use of HyperArc (HA) radiosurgery optimization and delivery in conjunction with multicriteria optimization (MCO) to create conformal and efficient treatment plans for conventionally fractionated radiation therapy to difficult base-of-skull (BOS) lesions.
Twelve patients with BOS meningioma were retrospectively planned with HA-specific optimization algorithm, stereotactic normal tissue objective (SRS-NTO), and conventional automatic normal tissue objective to evaluate normal brain sparing (mean dose and V20 Gy). MCO was used on both SRS-NTO and automatic normal tissue objective plans to further decrease organ-at-risk doses and target dose maximum to within clinically acceptable constraints. Delivery efficiency was evaluated based on planned monitor units.
The SRS-NTO in HA can be used to improve the mid- and low-dose spread to normal brain tissue in the irradiation of BOS meningiomas. Improvement in normal brain sparing can be seen in larger, more irregular shaped lesions and less so in smaller spherical targets. MCO can be used in conjunction with the SRS-NTO to reduce target dose maximum and dose to organ at risk without sacrificing the gain in normal brain sparing.
HA can be beneficial both in treatment planning by using the SRS-NTO and in delivery efficiency through the decrease in monitor units and automated delivery.
由于颅底脑膜瘤的靶区体积形状不规则且靠近关键视觉结构,其治疗计划制定可能具有挑战性。本研究评估了使用HyperArc(HA)放射外科优化和递送技术结合多标准优化(MCO),为传统分割放射治疗难以治疗的颅底(BOS)病变制定适形且高效的治疗计划。
对12例BOS脑膜瘤患者进行回顾性计划,采用HA特定优化算法、立体定向正常组织目标(SRS-NTO)和传统自动正常组织目标,以评估对正常脑组织的保护情况(平均剂量和V20 Gy)。在SRS-NTO和自动正常组织目标计划中均使用MCO,以进一步将危及器官剂量和靶区剂量最大值降低到临床可接受的范围内。根据计划的监测单位评估递送效率。
HA中的SRS-NTO可用于改善BOS脑膜瘤放疗中对正常脑组织的中低剂量分布。在较大、形状更不规则的病变中,对正常脑组织的保护改善更明显,而在较小的球形靶区中则不太明显。MCO可与SRS-NTO联合使用,在不牺牲对正常脑组织保护增益的情况下,降低靶区剂量最大值和危及器官剂量。
HA在使用SRS-NTO进行治疗计划制定以及通过减少监测单位和自动递送提高递送效率方面均有益处。